Premium
Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II
Author(s) -
Nieminen Markku S.,
Harjola VeliPekka,
Hochadel Matthias,
Drexler Helmut,
Komajda Michel,
Brutsaert Dirk,
Dickstein Kenneth,
Ponikowski Piotr,
Tavazzi Luigi,
Follath Ferenc,
LopezSendon Jose Luis
Publication year - 2008
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2007.12.012
Subject(s) - medicine , heart failure , atrial fibrillation , diabetes mellitus , etiology , cardiology , valvular heart disease , medical prescription , cardiomyopathy , dilated cardiomyopathy , hypertensive heart disease , pharmacology , endocrinology
Aims: This analysis evaluates the gender differences in patients hospitalised for acute heart failure (AHF) in the EuroHeart Failure Survey II (EHFS). Results: Of the 3580 patients included in EHFS II, 1384 (39%) were women, mean age 73 years. 2196 (61%) were men, mean age 68 years. Women more frequently had new‐onset AHF, hypertension and valvular disease and less frequently coronary heart disease or dilated cardiomyopathy compared with men. Smoking, chronic obstructive pulmonary disease, peripheral arterial disease and renal failure were less common, but diabetes and anaemia significantly more frequent in women. Atrial fibrillation and preserved left ventricular function were more common in women. Men were more often non‐compliant with medication. After adjustment for indications and age, there were no significant gender differences in prescription of HF medication. All‐cause readmission rate during the one‐year follow‐up was lower in women. However, the proportion of HF hospitalisation and one‐year mortality after discharge (20%) were similar in both genders. Conclusion: Women frequently present with new‐onset AHF. A significant gender difference exists in aetiology, ventricular function and co‐morbidities. Women's use of HF medication has improved. These findings emphasize the importance of individualised management and need for more comprehensive recruitment of women in clinical trials.